Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
| Status: | Recruiting |
|---|---|
| Conditions: | Hematology, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/10/2019 |
| Start Date: | November 2016 |
| End Date: | January 2023 |
| Contact: | Gillian Currie, BSc |
| Email: | currie.gillian@mayo.edu |
| Phone: | 507-293-0792 |
The use of genomics and functional translational studies is to identify and diagnose patients
with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.
with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.
The pre-myeloid cancer and bone marrow failure clinic is an individualized medicine clinic
conceptualized for the early detection of myeloid malignancies such as, myelodysplastic
syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and acute
myeloid leukemia (AML). Using next-generation sequencing technologies, clonal hematopoietic
stem cell changes can be detected early on in myeloid malignancies. These changes are
currently classified as follows:
1. Idiopathic cytopenias of unclear significance (ICUS).
2. Clonal cytopenias of unclear significance (CCUS).
3. Clonal hematopoiesis of indeterminate prognosis (CHIP).
4. Bone marrow failure syndromes with risk for clonal myeloid transformation.
5. Familial/Germline syndromes with increased risk for myeloid malignancies.
This clinic blends next-generation sequencing technologies with functional studies to help
identify, prognosticate and define management plans; including early intervention strategies,
for affected patients.
conceptualized for the early detection of myeloid malignancies such as, myelodysplastic
syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and acute
myeloid leukemia (AML). Using next-generation sequencing technologies, clonal hematopoietic
stem cell changes can be detected early on in myeloid malignancies. These changes are
currently classified as follows:
1. Idiopathic cytopenias of unclear significance (ICUS).
2. Clonal cytopenias of unclear significance (CCUS).
3. Clonal hematopoiesis of indeterminate prognosis (CHIP).
4. Bone marrow failure syndromes with risk for clonal myeloid transformation.
5. Familial/Germline syndromes with increased risk for myeloid malignancies.
This clinic blends next-generation sequencing technologies with functional studies to help
identify, prognosticate and define management plans; including early intervention strategies,
for affected patients.
Inclusion Criteria:
Patients with:
- Idiopathic cytopenias of unclear significance (ICUS)
- Clonal hematopoiesis of indeterminate significance (CHIP)
- Age related clonal hematopoiesis (ARCH)
- Clonal cytopenias of unclear significance (CCUS)
- Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction,
chromosomal breakage disorders, etc.
- Germ line inherited syndromes with risk for malignant transformation
- Low Risk Myelodysplastic Syndromes (MDS)
Exclusion Criteria:
- Patients who are unable to understand and sign the Informed Consent Form
We found this trial at
1
site
Click here to add this to my saved trials
